trending Market Intelligence /marketintelligence/en/news-insights/trending/G0WoaiY4npppFX0KFep32w2 content esgSubNav
In This List

Catabasis Pharmaceuticals to execute 1-for-10 reverse stock split

Blog

Global Capital Markets & SPAC Activity – H1 2021

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management


Catabasis Pharmaceuticals to execute 1-for-10 reverse stock split

Catabasis Pharmaceuticals Inc. said its shares will start trading on the Nasdaq Global Market on a 1-for-10 reverse split-adjusted basis on Dec. 31 under the symbol CATB.

The majority shareholders of the company approved the reverse stock split on Dec. 12 and authorized the board to select a ratio for the split ranging from 1-for-5 to 1-for-15.

The Catabasis board approved the reverse stock split on Dec. 19 to help the company maintain its listing on the Nasdaq Global Market by complying with the exchange's minimum bid price requirement.

The action reduces the number of the company's outstanding common shares to about 7.1 million from about 71 million.

Cambridge, Mass.-based Catabasis is developing a treatment for Duchenne muscular dystrophy.